

Growth Optimization of *Arthrospira platensis* SPKY1 for Insulin Production

K. Yuvarani  and A.K. Kathireshan* 

Department of Microbiology, School of Life Sciences, Vels University, Pallavaram, Chennai, Tamil Nadu, India.

Abstract

The escalating global burden of diabetes underscores the urgent need for sustainable insulin production. This study explores the potential of *Arthrospira platensis* SPKY1 as an alternative source of insulin, particularly pertinent in regions with high diabetes prevalence like India. Through comprehensive experimentation, factors influencing insulin production in *A. platensis* SPKY1 are investigated, including growth media composition, pH levels, light conditions, greenhouse cultivation, water types and carbon sources. Results reveal those higher concentrations of specific growth media components, such as NaHCO_3 , NaNO_3 , NaCl , K_2SO_4 , and K_2HPO_4 , correlate with increased insulin production. Among these components, K_2SO_4 at a concentration of 1.4 g L^{-1} showed the highest insulin production, reaching $27.5 \mu\text{g g}^{-1}$. Additionally, the study evaluated the impact of various pH levels, finding that pH 10.0 yielded optimal insulin production, with a peak of $21.3 \mu\text{g g}^{-1}$. Blue light exposure stimulated the most significant increase in insulin production, with levels ranging from 5.4 to $25.1 \mu\text{g g}^{-1}$. Additionally, enriched seawater proved more effective than regular medium for insulin production. The study also demonstrated that glucose proved to be the optimal carbon source, with insulin production reaching $29.4 \mu\text{g g}^{-1}$. The study determines the optimal growth conditions of *A. platensis* SPKY1 for insulin production on a pilot scale.

Keywords: Antidiabetic, Anti-glycemic, *Arthrospira*, Diabetes, Insulin

*Correspondence: kathirhodmicrobiology@gmail.com

Citation: Yuvarani K, Kathireshan AK. Growth Optimization of *Arthrospira platensis* SPKY1 for Insulin Production. *J Pure Appl Microbiol.* 2025;19(2):1479-1492. doi: 10.22207/JPAM.19.2.53

© The Author(s) 2025. **Open Access.** This article is distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

INTRODUCTION

Diabetes poses a significant and enduring challenge, characterized by elevated blood sugar levels stemming from irregularities in β -cell function affecting insulin activity.¹ According to the International Diabetes Federation (IDF), the global prevalence of diabetes reached 537 million individuals in 2021, representing a substantial burden on healthcare systems.^{2,3} Age-standardized prevalence rates surged by approximately 90.5% from 1990 to 2021, with particularly notable increases of over 90% in regions such as South Asia, Western and Eastern Europe, and over 100% in areas including Central Asia, Southern Latin America, and high-income North America. In contrast, some regions experienced more moderate rises, with increases of less than 30% noted in countries like Mexico and the Philippines, while others saw dramatic spikes of up to 200%, as seen in nations like Egypt, Greenland, and Timor-Leste.⁴

According to a 2023 study by the Indian Council of Medical Research (ICMR), 11.4% of India's population, amounting to 101 million individuals, are diagnosed with diabetes. The prevalence of diabetes varied significantly across different states, ranging from 4.8% to 26.4%. Specifically, Jharkhand, Nagaland, Manipur, and Punjab exhibited prevalence rates between 5.0% and 9.9%, while Tamil Nadu, Andhra Pradesh, Karnataka, Maharashtra, Gujarat, and Bihar reported rates from 10.4% to 14.9%. Additionally, Kerala, Madhya Pradesh, Rajasthan, West Bengal, and Himachal Pradesh had prevalence rates exceeding 15%. Diabetes prevalence was significantly elevated in both the southern and northern parts of India, with urban areas consistently demonstrating elevated prevalence rates. Conversely, the central and north eastern regions displayed lower prevalence rates.⁵

Diabetes has the potential to affect various organ systems in the body, leading to severe complications over time. These complications are typically classified as either microvascular or macrovascular. Microvascular complications involve damage to the nervous system (neuropathy), renal system (nephropathy), and eyes (retinopathy). On the other hand, macrovascular complications include cardiovascular disease, stroke, and

peripheral vascular disease. Peripheral vascular disease can result in non-healing bruises or injuries, gangrene, and ultimately, the need for amputation.⁶ These complications not only significantly impact the morbidity and mortality associated with diabetes but also contribute to the growing costs related to its management.

Currently, the primary therapeutic regimens for type 2 diabetes mellitus (T2DM) involve the injection of insulin-like agents and the oral administration of hypoglycemic agents. However, while these agents are crucial for T2DM treatment, they often come with undesirable side effects.^{7,8} Insulin has been at the forefront of managing uncontrolled insulin-deficient DM since its discovery.⁹

Insulin is a vital medication for managing both T1DM and T2DM, recognized by the World Health Organization (WHO) as an Essential Medicine necessary for addressing global health needs and promoting cost-effective healthcare resource utilization.¹⁰ Despite being discovered almost a century ago, insulin remains inaccessible to millions due to inadequate availability and excessively high prices.^{11,12}

In India, select insulin products are listed in both national and state Essential Medicines Lists (EMLs), allowing for their free provision in public-sector health facilities.¹³ However, limited funding for India's central and state public health systems restricts healthcare coverage for much of the population.¹⁴ As a result, diabetes patients often turn to the private sector for healthcare, necessitating out-of-pocket payments.¹⁵ Additionally, patients may acquire medications from private-sector online pharmacies or government initiatives like the Jan Aushadhi Scheme (JAS), aimed at providing quality medicines at affordable prices to all.^{16,17}

Exploring alternative sources for insulin production is crucial for overcoming the challenges of cost and accessibility. By investigating microorganisms, plant-based systems, researchers aim to develop more affordable and scalable methods for producing insulin. These innovative approaches have the potential to significantly reduce production costs, making insulin more accessible to individuals worldwide who depend on this essential medication for managing diabetes. Spirulina has garnered attention for its

potential anti-diabetic properties. A study suggests that *Spirulina* may help regulate blood sugar levels by improving insulin sensitivity and reducing insulin resistance.¹⁸

Research on *Spirulina* supplementation for lowering blood sugar levels has not pinpointed the specific molecules responsible for its anti-diabetic effects. However, despite the absence of whole genome sequencing in these studies, a recent investigation identified a potentially beneficial strain, *A. platensis* SPKY1. This strain was subjected to whole genome sequencing and subsequently submitted to NCBI (GenBank ID: JAWMAM000000000.1). Insulin production was validated using multiple analytical techniques, including protein quantification, SDS-PAGE, 2D gel electrophoresis, and MALDI, all consistently detecting a 6 kDa band, aligning with prior insulin identification studies. The genome size of *A. platensis* SPKY1 was found to be 5.7 Mb, with a total of 7,731 genes encoding hypothetical proteins. Gene analysis revealed four unique hypothetical proteins, each made up of six amino acid residues, that perfectly match human insulin. Furthermore, eight proteins belonging to the insulinase family were discovered.¹⁹ Therefore, the primary aim of this study is to investigate the optimal growth conditions for *A. platensis* SPKY1 to enhance insulin production on a pilot scale.

MATERIALS AND METHODS

The *A. platensis* SPKY1 used in this study were isolated from Ennore estuary, Chennai, Tamil Nadu. The strain is identified through whole genome sequencing and compared with the NCBI WGS database. *A. platensis* SPKY1 showed high similarity to *A. platensis*. However, due to the presence of insulinase, the strain is designated as *A. platensis* SPKY1.

Unialgal culture

Obtaining unialgal cultures is essential for the study. As a first step, the collected water was filtered using mesh cloth, followed by filtration through a 47- μm pore membrane. The pH of the collected water was then adjusted to 12 and maintained for 48 hours. After incubation, the pH was lowered to 9 using a bicarbonate buffer.

To eliminate contamination, the culture was treated with cefoxitin ($76.9 \mu\text{g mL}^{-1}$) for 48 hours in the dark. Following incubation, the culture was washed by centrifugation at 2000 rpm for 5 minutes. Unialgal *A. platensis* SPKY1 cultures were obtained through serial dilution (1:1000). Cultures were examined under a microscope to identify contaminants before each experiment. All subsequent experiments utilized cultures derived from this mother culture (control).

Growth conditions

Analytical-grade chemicals were used, and the medium was sterilized at 120°C for 15 minutes prior to inoculation, with pH checked to ensure suitability. Clean conical flasks were used and maintained at a constant temperature below 30°C , typically around 21°C . Stock cultures were maintained on agar slants, and before inoculation, cultures were examined for contaminants under a microscope. For inoculum preparation, a portion of the stock culture was shaken with sterile medium. 50 mL of the suspension were inoculated into freshly prepared Zarrouk's medium.²⁰ Illumination was provided by cool white fluorescent lamps at a light intensity of $50 \mu\text{mol photons m}^{-2} \text{ s}^{-1}$, measured using a Lutron Lx-130 light meter, with a 12-hour light-dark cycle. The culture was maintained for 20 days, after which the algae and medium were separated by centrifugation, washed, and the biomass yield was determined following the procedure of Donmez *et al.*²¹

Effect of media manipulation

A. platensis SPKY1 was grown in different concentrations of NaHCO_3 (14.8-18.8 g), NaNO_3 (1.5-3.5 g), NaCl (0.6 to 1.4 g), K_2SO_4 (0.6 to 1.4 g), K_2HPO_4 (0.3 to 0.7 g) remaining ingredients were kept constant as regular standard Zarrouk's medium. Due to production cost concerns, this study examined the impact of varying the composition of Zarrouk's medium from the standard formula. All medium manipulated cultures were compared with controlled *A. platensis* SPKY1 culture which was grown in standard Zarrouk's medium.

Effect of pH

The effect of pH on *A. platensis* SPKY1 growth and insulin production was evaluated

using Zarrouk's medium adjusted to pH levels ranging from 7.0 to 12.0. At the start of the experiment, the pH was adjusted using 8 M NaOH or 1 N HCl solutions. For the experiment, 2000 mL Erlenmeyer flasks containing 1000 mL of medium were prepared, with the pH adjusted before autoclaving. A two-week-old *A. platensis* SPKY1 mother culture was uniformly inoculated into all flasks, which were subsequently incubated for 20 days.

Effect of light

To assess the impact of light on insulin production, various lighting conditions were employed using colored LEDs. The LEDs generated light in the following spectral ranges: red (620-680 nm), blue (420-475 nm), green (495-570 nm), and yellow (570-590 nm), with an intensity of 150 $\mu\text{mol photons}\cdot\text{m}^{-2}\cdot\text{s}^{-1}$ measured using a Lutron LX-130 light meter. Freshly prepared standard culture media (1000 mL) were inoculated with the *A. platensis* SPKY1 mother culture. Each culture was exposed to illumination from LEDs emitting the designated color. To ensure that only the intended light spectrum reached the cultures, they were housed in specially constructed boxes that excluded external light interference.

Effect of culture system

The effect of the cultivation system on *A. platensis* SPKY1 growth and insulin production was evaluated using an open cultivation and green house setup. Open system: In this setup, the mother culture was exposed to ambient air and directly illuminated by sunlight in open plastic trays, each with a capacity of 10 L. Greenhouse effect: To study the impact of solar irradiance, greenhouse nets were used to partially cover the trays, reducing light intensity. Both setups (open system and green house trays) were maintained in separate locations within a 10 meter radius to minimize cross-interference and potential contamination.

Effect of water type

5 L of seawater was collected from Ennore estuary. Initially the collected water was filtered with mesh to remove larger and smaller waste particles. The mother culture was inoculated in Zarrouk's medium prepared using seawater (Enrich

medium) and only sea water (without addition of nutrients). Both media were sterilized by using autoclaving before inoculation and growth was compared with mother culture growth in Zarrouk's medium prepared using distilled water.

Effect of organic carbon sources

In order to identify the optimal growth based on the carbon source availability, various concentrations of organic carbon sources (glucose, fructose, galactose, sucrose and glycerol) were added at different concentrations (0.5-1.5 g L^{-1}) in the standard Zarrouk's medium.

Insulin estimation

To extract insulin from biomass after applying various strain improvement techniques, a series of steps were followed according to Khanna *et al.*²² Insulin ELISA kit was purchased from Genei Laboratories Pvt. Ltd., Bangalore. Extracted insulin from all treated culture was estimated by following procedure. Prepare the ELISA plate by setting standard, test sample (diluted at least 1/2 with sample dilution buffer), and control (zero) wells, then aliquot 100 μL of standard solutions into the standard wells, add 100 μL of sample dilution buffer into the control well, and add 100 μL of properly diluted sample into test sample wells. Incubate the plate at 37 °C for 90 minutes, and then wash it 2 times with wash buffer. Carefully add 100 μL of the Biotin-labeled antibody working solution to each well, ensuring not to touch the side walls. Incubate the plate at 37 °C for 60 minutes, then wash it three times using wash buffer. Next, dispense 100 μL of HRP-Streptavidin Conjugate working solution into each well, cover the plate, and incubate at 37 °C for 30 minutes. Wash the plate five times with wash buffer. Following this, add 90 μL of 3,3',5,5'-Tetramethylbenzidine (TMB) substrate to each well, cover, and incubate at 37 °C in the dark for 10-20 minutes. To halt the reaction, introduce 50 μL of stop solution into each well, mix thoroughly, and immediately measure the Optical Density (OD) absorbance at 450 nm using a microplate reader.

For data analysis, determine the mean OD 450 nm values from duplicate readings of each standard, control, and sample. Subtract the OD 450 nm blank to obtain the corrected OD 450 nm values. Construct a four-parameter logistic (4PL)

standard curve by plotting the mean absorbance for each standard against its concentration. Finally, determine the sample concentration by interpolating the OD 450 nm value from the standard curve, adjusting for any dilution factor applied.²³

Statistical analysis

Each experiment in this study conducted in five 1000 mL flask and data were analysed using SPSS software (Version 25). Mean values and standard deviations (SD) of insulin concentration were measured. A two-sided t was used to compare all treated cultures and the absolute difference was analysed and reported with 95% confidence interval. A p-value of less than 0.05 was considered significant. The data were checked for normality, homogeneity of variance, and outliers before conducting the analysis to ensure the accuracy and validity of the analysis. Significance differences in insulin level between different concentrations of each treated cultures were analyzed using one-way ANOVA. The forest plot represents odds ratios (OR) with 95% confidence intervals (CI) for insulin production under different experimental conditions. The red dashed line at OR = 1 indicates the control. OR greater than 1 represents increased insulin production relative to the control, while values below 1 indicate reduced production.

RESULTS

The study investigated the potential of *A. platensis* SPKY1 as an alternative source of insulin, focusing on optimizing factors influencing its production. Key variables assessed included growth media composition, pH levels, light conditions, greenhouse cultivation, water types, and carbon sources. The data investigates the effect of media manipulation on insulin production, focusing on additives such as NaHCO₃, NaNO₃, NaCl, K₂SO₄, and K₂HPO₄. The results show that cultures treated with 1.4 g L⁻¹ of K₂SO₄ and 17.8 g L⁻¹ of NaHCO₃ produced 72.9% and 60.3% higher insulin production, respectively, compared to the control culture. Conversely, NaCl and K₂HPO₄ consistently demonstrated enhanced insulin production of 52.8% and 47.7%, respectively, when compared to the control culture. Lower concentrations of

these additives often led to significantly decreased insulin production compared to the mother culture (Table 1).

Figure 1 demonstrates the OR and 95% CI for insulin production under various media optimization conditions compared to control cultures (OR = 1). For NaHCO₃, insulin production decreases at 14.8 g L⁻¹ (OR = 0.7, CI: 0.5-0.9) and 15.8 g L⁻¹ (OR = 0.9, CI: 0.7-1.1) but significantly increases at 17.8 g L⁻¹ (OR = 1.6, CI: 1.4-1.8), before declining slightly at 18.8 g L⁻¹ (OR = 1.2, CI: 1.0-1.4). For NaNO₃, lower concentrations (1.5 g L⁻¹, OR = 0.7, CI: 0.4-0.9; 2 g L⁻¹, OR = 0.9, CI: 0.7-1.1) reduce production, while higher concentrations (3 g L⁻¹, OR = 1.3, CI: 1.0-1.6; 3.5 g L⁻¹, OR = 1.7, CI: 1.5-2.0) enhance it. NaCl shows a steady increase in insulin production from 0.6 g L⁻¹ (OR = 0.9, CI: 0.7-1.2) to 1.4 g L⁻¹ (OR = 1.5, CI: 1.2-1.7). Similarly, K₂SO₄ improves production, starting at 0.6 g L⁻¹ (OR = 0.9, CI: 0.6-1.2) and peaking at 1.4 g L⁻¹ (OR = 1.7, CI: 1.5-1.9). For K₂HPO₄, production is lowest at 0.3 g L⁻¹ (OR = 0.7, CI: 0.5-1.0) but increases with concentration, reaching a maximum at 0.7 g L⁻¹ (OR = 1.5, CI: 1.2-1.7).

Table 2 illustrates various growth conditions aimed at optimizing insulin production through adjustments in pH levels, light color, culture systems, and water types. The results show that increasing pH generally correlates with higher insulin production. The maximum insulin production (33.9%) was observed at pH 10, compared to the control culture. A similar positive trend was noted with different light colors, with blue light resulting in the most significant increase (57.8%) in insulin production, while yellow light showed the least growth compared to the control culture. Regarding culture systems, the greenhouse system produced 10.7% higher insulin production compared to the control culture. Finally, the highest insulin production (59.7%) was observed in enriched seawater, compared to the control culture.

Figure 2 illustrates the odds ratios for insulin production under varying conditions, with the OR = 1 representing the control. For pH levels, insulin production increases with pH, reaching a peak at pH 10 (OR = 1.3, CI: 1.1-1.5) and remaining stable at higher levels. For light color, blue light demonstrates the highest enhancement in insulin production (OR = 1.6, CI: 1.4-1.8), followed

Table 1. Optimization of insulin production through media manipulation

Media Manipulation gL ⁻¹	Insulin (µg g) (n = 5) Mean ± SD				p*	p**	Mean Difference from control culture at 20 th Day (15.9 µg g ⁻¹) Mean (CI) p [#]
	5 th Day	10 th Day	15 th Day	20 th Day			
NaHCO₃							
14.8	2.4 ± 0.2	4.0 ± 0.3	8.1 ± 0.1	11.4 ± 0.2	0.004	<0.001	-4.4 (-4.9, -3.9) 0.001
15.8	2.7 ± 0.1	5.7 ± 0.1	9.5 ± 0.3	14.5 ± 0.3	0.001		-1.4 (-2.0, -0.7) 0.012
17.8	4.3 ± 0.3	9.7 ± 0.3	14.8 ± 0.4	25.5 ± 0.4	0.001		9.6 (8.8, 10.4) 0.001
18.8	3.3 ± 0.1	8.5 ± 0.4	12.3 ± 0.3	19.3 ± 0.3	0.002		3.4 (2.8, 4.0) 0.002
NaNO₃							
1.5	1.8 ± 0.1	4.2 ± 0.2	6.4 ± 0.2	10.5 ± 0.2	0.002	<0.001	-5.3 (-5.7, -4.9) 0.001
2.0	2.4 ± 0.2	5.3 ± 0.2	8.5 ± 0.2	13.6 ± 0.3	0.002		-2.3 (-2.9, -1.6) 0.004
3.0	3.8 ± 0.1	7.8 ± 0.2	13.3 ± 0.4	20.4 ± 0.4	0.001		4.5 (4.2, 4.7) 0.001
3.5	4.3 ± 0.2	9.4 ± 0.3	14.9 ± 0.3	26.6 ± 0.6	0.002		10.7 (9.7, 11.6) 0.001
NaCl							
0.6	2.9 ± 0.4	6.4 ± 0.2	8.8 ± 0.3	14.4 ± 0.2	0.001	<0.001	-1.5 (-1.9, -1.0) 0.006
0.8	3.5 ± 0.2	7.4 ± 0.2	10.3 ± 0.3	15.2 ± 0.3	<0.001		-0.6 (-1.1, -0.2) 0.031
1.2	4.3 ± 0.3	8.2 ± 0.3	14.4 ± 0.3	22.5 ± 0.3	<0.001		6.6 (6.1, 7.1) 0.001
1.4	5.0 ± 0.3	9.1 ± 0.2	15.6 ± 0.3	24.3 ± 0.3	<0.001		8.4 (7.9, 8.9) 0.001
K₂SO₄							
0.6	3.6 ± 0.2	5.6 ± 0.3	8.4 ± 0.4	14.2 ± 0.4	<0.001	<0.001	-1.7 (-2.4, -0.9) 0.010
0.8	3.8 ± 0.3	6.7 ± 0.3	10.4 ± 0.2	15.3 ± 0.3	<0.001		-0.6 (-1.1, -0.3) 0.031
1.2	4.8 ± 0.2	7.6 ± 0.2	16.7 ± 0.3	21.5 ± 0.3	<0.001		5.6 (5.1, 6.1) 0.001
1.4	5.3 ± 0.2	8.4 ± 0.3	18.4 ± 0.2	27.5 ± 0.3	<0.001		11.6 (11.1, 12.0) 0.001
K₂HPO₄							
0.3	3.3 ± 0.4	5.7 ± 0.3	8.5 ± 0.2	11.3 ± 0.4	<0.001	<0.001	-4.6 (-4.8, -4.3) 0.001
0.4	4.1 ± 0.3	6.6 ± 0.3	11.7 ± 0.3	14.7 ± 0.3	<0.001		-1.2 (-1.6, -0.7) 0.007
0.6	4.6 ± 0.2	7.5 ± 0.3	15.6 ± 0.3	20.6 ± 0.4	<0.001		4.7 (4.2, 5.1) 0.001
0.7	4.7 ± 0.3	7.4 ± 0.3	17.5 ± 0.3	23.5 ± .4	<0.001		7.6 (7.3, 7.9) 0.001

*- significance from 5th-20th day, **- significance within groups, #- significance between treated and control cultures

by green light (OR = 1.4, CI: 1.1-1.7). Culture systems show a minor increase in production in greenhouses (OR = 1.1, CI: 0.9-1.4) compared to open systems. Water type reveals enriched seawater as most effective (OR = 1.6, CI: 1.4-1.8), while regular seawater also enhances production (OR = 1.3, CI: 1.1-1.5).

Table 3 illustrates various growth conditions aimed at optimizing insulin production through various carbon sources at different concentrations. Result shows that the maximum insulin production compared to the control culture at the 20th day was observed with glucose at 85.9% higher than the control, followed by fructose with a 78.3% increase. Galactose showed a 47.2% enhancement in insulin production, while sucrose resulted in a more modest 17.6% increase. Glycerol

produced the least impact, with only an 11.3% increase in insulin production compared to the control culture.

Figure 3 demonstrates the odds ratios and 95% confidence intervals for insulin production across various sugar types and concentrations compared to control cultures (OR = 1). Glucose and fructose show a strong dose-dependent increase in insulin production, with glucose peaking at 1.5 g L⁻¹ (OR = 1.8, CI: 1.3-2.2) and fructose at the same concentration (OR = 1.8, CI: 1.3-2.0). Galactose exhibits moderate effects, with the highest OR of 1.5 at 1.5 g L⁻¹ (CI: 1.1-1.9), while sucrose shows smaller improvements, reaching an OR of 1.2 at 1.5 g L⁻¹ (CI: 0.9-1.6). Glycerol has minimal influence, with OR values remaining relatively stable across concentrations, peaking at 1.1 (CI: 0.9-1.4).

Table 2. Growth optimization for insulin production

Growth conditions	Insulin ($\mu\text{g g}^{-1}$) (n = 5) Mean \pm SD				p*	P**	Mean Difference from control culture at 20 th Day (15.9 $\mu\text{g g}^{-1}$) Mean (CI) p [#]
	5 th Day	10 th Day	15 th Day	20 th Day			
pH							
7	3.5 \pm 0.07	5.1 \pm 0.1	9.0 \pm 0.07	13.1 \pm 0.1	<0.001	0.025	-2.8 (-3.0, -2.5) 0.023
8	3.8 \pm 0.03	6.1 \pm 0.08	11.2 \pm 0.1	16.4 \pm 0.9	<0.001		0.5 (0.3, 0.7) 0.048
9	4.4 \pm 0.07	8.1 \pm 0.2	14.4 \pm 0.1	19.5 \pm 0.07	<0.001		3.6 (3.3, 3.8) 0.009
10	4.7 \pm 0.3	9.8 \pm 0.1	17.1 \pm 0.1	21.3 \pm 0.4	<0.001		5.4 (4.6, 6.2) 0.001
11	4.7 \pm 0.03	7.4 \pm 0.1	11.1 \pm 0.2	18.3 \pm 0.2	<0.001		2.4 (2.0, 2.8) 0.001
12	4.1 \pm 0.1	6.8 \pm 0.3	8.2 \pm 0.06	19.1 \pm 0.2	<0.001		3.2 (3.0, 3.6) 0.001
Light colour							
Red	4.5 \pm 0.4	7.5 \pm 0.1	11.2 \pm 0.2	17.3 \pm 0.2	<0.001	0.019	1.4 (1.1, 1.8) 0.007
Blue	5.4 \pm 0.4	9.1 \pm 0.1	15.2 \pm 0.2	25.1 \pm 0.6	<0.001		9.2 (8.8, 10.2) 0.005
Green	4.6 \pm 0.4	8.6 \pm 0.3	14.3 \pm 0.3	22.4 \pm 0.3	0.002		6.5 (6.0, 7.1) 0.001
Yellow	3.4 \pm 0.2	6.2 \pm 0.2	10.6 \pm 0.3	18.4 \pm 0.4	0.001		2.5 (1.8, 3.1) 0.001
Culture system							
Open system	2.3 \pm 0.2	5.2 \pm 0.2	8.3 \pm 0.1	16.4 \pm 0.3	0.004	0.039	0.5 (0.3, 0.6) 0.005
Greenhouse	4.1 \pm 0.2	7.5 \pm 0.3	11.3 \pm 0.4	17.6 \pm 0.1	0.001		1.7 (1.4, 1.9) 0.003
Water type							
Sea water	4.9 \pm 0.1	7.8 \pm 0.2	14.7 \pm 0.1	20.5 \pm 0.3	0.001	0.015	4.6 (4.0, 5.1) 0.002
Enrich Sea water	5.6 \pm 0.1	9.5 \pm 0.2	16.7 \pm 0.1	25.4 \pm 0.3	0.001		9.5 (9.1, 9.7) 0.001

*- significance from 5th-20th day, **- significance within groups, #- significance between treated and control cultures

DISCUSSION

India, with a population exceeding 1.4 billion, has a significant burden of diabetes. According to the IDF, the country has one of the highest numbers of people living with diabetes worldwide, with estimates suggesting over 77 million cases in 2021. This high prevalence of diabetes drives a substantial demand for insulin, which is a vital component in the management of diabetes, especially for T1DM and some cases of T2DM requiring insulin therapy. As awareness and diagnosis rates of diabetes improve, more people are prescribed insulin, leading to increased demand. Despite India's growing demand for insulin, affordability and accessibility remain significant challenges. Many people with diabetes face economic barriers to accessing insulin, leading to disparities in treatment outcomes.²⁴

The production of insulin using *Escherichia coli* (*E. coli*) has been the standard method since the 1980s when recombinant DNA technology revolutionized insulin manufacturing. This approach is used to produce large quantities of

human insulin and insulin analogs for diabetes treatment.^{25,26} However, *E. coli*-based production has its challenges, including high costs, complex purification processes, and stringent regulatory requirements.²⁷ As a result, there is a growing interest in finding alternative sources for insulin production that are easier to cultivate and more cost-effective.

Spirulina has been harvested for centuries by various indigenous cultures as a valuable food source.²⁸ It is renowned for its rich nutrient profile, making it a popular supplement and a key component in traditional diets.²⁹ Despite its established benefits, it has yet to attract significant attention as a potential source of insulin production. Studies have reported that blood glucose,^{30,31} and HbA1c,^{32,33} level was decreased and insulin level,^{34,35} was increased in human and animal model by Spirulina supplementation. But these studies not isolated and identified any bio molecules responsible for this reduction glucose level.

The first study by Sliva *et al.*³⁶ identified the presence of insulin in *Spirulina maxima*;

however, the insulin levels in these species were not specified. Subsequently, research by Razique Anwer *et al.*³⁷ confirmed insulin presence in 16 out of 23 *Arthrospira* strains screened. But this study evaluated only effect of media alternation for optimizing the insulin production. Recently the *A. platensis* SPKY1 have been isolated from Ennore estuary shows the presence of insulin and eight insulinase family protein.¹⁹ The insulin production by *A. platensis* SPKY1 was $15.9 \mu\text{g g}^{-1}$ at 20th day, which is lesser than the *S. platensis* (CFTRI, Mysore) reported by Anwer *et al.*³⁷ In the present study, *A. platensis* SPKY1 were exposed to various strain improvement strategies to enhance the insulin production.

Comparing the results of insulin production with the findings of Anwer *et al.*,³⁷ on *S. platensis* (CFTRI, Mysore). We can observe some parallels and distinctions in how different media components affect insulin production. Both in *A. platensis* SPKY1 and *S. platensis* (CFTRI, Mysore) insulin production generally increases with higher concentrations of various media components, demonstrating a dose-response relationship. In *A. platensis* SPKY1, we see a steady increase in insulin production with higher concentrations of NaHCO_3 . Specifically, at 17.8 g L^{-1} , insulin production on the 20th day reaches $25.5 \mu\text{g g}^{-1}$, significantly exceeding the mother culture. Maximum insulin content (5.6%) with




Figure 1. Forest plot for odd ratios with 95% CI for insulin production by media optimization cultures compare to control culture

Table 3. Optimization of insulin production by various concentrations of carbon sources

Carbon source (g L ⁻¹)	Insulin (µg g ⁻¹) Mean ± SD				p*	p**	Mean Difference from control culture at 20 th Day (15.9 µg g ⁻¹) Mean (CI) p#
	5 th Day	10 th Day	15 th Day	20 th Day			
Glucose							
0.5	4.4 ± 0.2	7.3 ± 0.2	11.7 ± 0.2	18.1 ± 0.3	<0.001	0.001	2.2 (1.4, 2.8) 0.006
1.0	5.4 ± 0.2	9.3 ± 0.3	16.4 ± 0.1	22.4 ± 0.4	<0.001		6.5 (5.5, 7.4) 0.001
1.5	8.4 ± 0.1	12.5 ± 0.1	23.3 ± 0.3	29.4 ± 0.3	<0.001		13.5 (13.2, 13.9) 0.001
Fructose							
0.5	3.5 ± 0.1	6.3 ± 0.2	10.3 ± 0.1	17.2 ± 0.2	<0.001	0.001	1.3 (0.7, 1.9) 0.011
1.0	4.7 ± 0.1	8.5 ± 0.2	15.0 ± 0.2	20.5 ± 0.2	<0.001		4.6 (4.1, 5.0) 0.001
1.5	7.3 ± 0.1	11.6 ± 0.2	19.3 ± 0.1	28.4 ± 0.3	<0.001		12.5 (12.2, 12.8) 0.001
Galactose							
0.5	3.5 ± 0.2	5.5 ± 0.2	9.5 ± 0.3	16.6 ± 0.3	<0.001	0.001	0.7 (0.2, 1.6) 0.049
1.0	5.3 ± 0.2	8.0 ± 0.2	13.6 ± 0.2	18.7 ± 0.2	<0.001		2.8 (2.1, 3.4) 0.003
1.5	7.2 ± 0.2	10.4 ± 0.1	17.5 ± 0.3	23.4 ± 0.2	<0.001		7.5 (7.2, 7.8) 0.001
Sucrose							
0.5	3.3 ± 0.1	4.3 ± 0.2	10.4 ± 0.2	16.6 ± 0.2	<0.001	0.264	0.7 (0.2, 1.3) 0.029
1.0	3.7 ± 0.1	5.1 ± 0.2	12.5 ± 0.3	17.4 ± 0.2	<0.001		1.5 (1.0, 2.0) 0.006
1.5	3.5 ± 0.4	5.4 ± 0.3	13.7 ± 0.3	18.7 ± 0.3	<0.001		2.7 (1.9, 3.4) 0.004
Glycerol							
0.5	3.5 ± 0.2	5.7 ± 0.2	11.4 ± 0.2	16.1 ± 0.4	<0.001	0.490	0.3 (-0.1, 0.6) 0.094
1.0	3.6 ± 0.2	5.4 ± 0.4	12.4 ± 0.2	16.7 ± 0.2	<0.001		0.8 (0.3, 1.3) 0.020
1.5	3.5 ± 0.3	5.6 ± 0.3	13.3 ± 0.2	17.7 ± 0.2	<0.001		1.8 (1.2, 2.4) 0.005

*- significance from 5th-20th day, **- significance within groups, #- significance between treated and control cultures

180 mM NaHCO₃ on day 12, was reported in *S. platensis* (CFTRI, Mysore) indicating that insulin production increases with this component but shows a decline after the peak point. In *A. platensis* SPKY1 shows that insulin production reaches 26.6 µg g⁻¹ with NaNO₃, indicating a steady increase with higher concentrations. Similarly, *S. platensis* (CFTRI, Mysore) noted the highest increase in insulin content (22.14%) at 55 mM NaNO₃ on day 12, suggesting that this compound is effective at promoting insulin production. Our results show that NaCl contributes to insulin production in a more gradual manner compared to other media components. At a 1.4 g L concentration, insulin production reaches 24.3 µg g⁻¹. Anwer *et al.*,³⁷ do not report specific values for NaCl, highlighting a potential area where our results diverge or offer additional insights. The production of insulin with K₂SO₄ appears somewhat variable across different

concentrations in our data. At 1.4 g L⁻¹, it shows a significant increase in insulin production, reaching 27.5 µg g⁻¹, the highest among all components. *S. platensis* (CFTRI, Mysore) shows increase in insulin levels of up to 26% with sulfate additions, reinforcing the idea that K₂SO₄ can significantly boost insulin production. Our data demonstrates that insulin production increases with higher concentrations of K₂HPO₄, with a maximum of 23.5 µg g⁻¹ at 0.7 g L⁻¹. It was reported that in *S. platensis* (CFTRI, Mysore) an increase of 3.75% in insulin content when K₂HPO₄ was added at 5.5 mM, indicating that while K₂HPO₄ has an impact, it may not be as pronounced as with other components.

In this study, *A. platensis* SPKY1 insulin production was assessed across various pH levels, with the highest production (21.3 µg g⁻¹) observed at pH 10.0. This can be attributed to the optimal enzymatic activities associated with

both photosynthesis and respiration within this pH range.³⁸ Prior research has indicated that a pH of 10.0 fosters an ideal environment for *S. platensis* growth and nutrient synthesis, resulting in increased biomass, protein, carbohydrate, and pigment production.³⁹ Present findings align closely with those of Abd El-Baky *et al.*,⁴⁰ who noted optimal growth and chemical production in *S. platensis* and *S. maxima* at pH 10.5. Similarly, Rafiqi *et al.*,⁴¹ reported maximal protein contents in *S. platensis* and *S. fusiformis* at pH 9.0 and 10.0, respectively. A study has consistently highlighted pH 10.0 as the point of optimization for *S. platensis* growth.⁴²

The data suggests that light color plays a significant role in insulin production from *A. platensis* SPKY1. Across all observations, there is a noticeable increase in insulin production when exposed to different colors of light over time. Blue light appears to stimulate the highest insulin production (5.4 to 25.1 $\mu\text{g g}^{-1}$). This rapid increase suggests that blue light is particularly effective in enhancing insulin production in *A. platensis* SPKY1. Notably, red light results in a moderate increase in insulin production, green and yellow light also support insulin production, but to varying extents. Studies have found that blue light enhance the biomass and protein content in *Spirulina* sp.⁴³⁻⁴⁵ In contrast, a study have reported that spirulina




Figure 2. Forest plot for odd ratios with 95% CI for insulin production by growth optimization cultures compare to control culture

growth was observed lesser in blue light compared to orange and white light.⁴⁶

The results of the present study suggest that a controlled greenhouse system may be more effective than an open system for cultivating *Spirulina* for insulin production. This suggests that the greenhouse system consistently produces higher insulin levels than the open system. The consistent increase in insulin production in the greenhouse system could be due to better environmental control, allowing for optimized growth conditions and reduced contamination

risk. A study reported that *Spirulina* grown in jars, bags and ponds under greenhouse effect enhance the biomass and protein content.⁴⁷ Another study shows that *S. platensis* produced 1.73 g L under greenhouse effect.⁴⁸

The study investigated the impact of different water types on insulin production in *Spirulina*. The results demonstrated that enriched sea water led to higher insulin production than regular sea water over the same period. The enriched sea water contains additional essential nutrients and minerals that promote *Spirulina*




Figure 3. Forest plot for odd ratios with 95% CI for insulin production by various carbon sources treated cultures compare to control culture

growth and metabolic activity, leading to increased insulin synthesis. In contrast, regular sea water has a lower nutrient concentration, which may limit *Spirulina* growth and thus result in lower insulin production. Similarly, a study reported a large-scale cultivation of *Spirulina* grown in sea water enriched with NaHCO_3 and FeSO_4 shows the average biomass (10.3 g) and protein (66.6%) production.⁴⁹ Another study reported that *Spirulina* biomass production was enhanced in medium enriched with sea salt (NaCl 40 g L⁻¹). In contrast a study did not find any significant growth in sea water.⁵⁰

The production of insulin across different carbon sources and varying concentrations over a 20-day period was examined. Across all carbon sources, the insulin production generally increased from the 5th to the 20th day. This suggests that the system is responsive to the carbon source and that the production process becomes more efficient as time progresses.

Glucose had the highest insulin production, especially at the higher concentrations reached 29.4 $\mu\text{g g}^{-1}$, a significant increase from the mother culture. This indicates that glucose is a potent carbon source for insulin production. Fructose and galactose both had moderate results. Sucrose and glycerol had relatively lower results compared to glucose, fructose, and galactose indicating that these are less efficient carbon sources for insulin production. Research indicated that cyanobacterial growth rates were boosted by all carbon sources except lactose. The highest growth rate of *S. platensis* occurred on the fourth day of cultivation when glucose, fructose, and succinate were present.⁵¹ These findings are consistent with previous studies. The concentration of glucose notably impacted biomass yield, with *C. protothecoides* and *C. saccharophila* exhibiting heterotrophic growth and yielding higher biomass when organic compounds were used as carbon sources.^{52,53} In contrast, other studies found that elevated carbon source concentrations could inhibit microalgal growth.^{54,55}

CONCLUSION

The top-performing *Spirulina* strains identified in this study, showing the highest levels of insulin production, will be selected for gene

expression analysis and pilot-scale production. By examining these strains, gene expression profiles, we can identify the specific genes responsible for increased insulin synthesis, allowing for targeted genetic modifications or culture optimizations to further boost production. Pilot-scale production will provide insights into the commercial viability of these strains, helping to bridge the gap between laboratory-scale research and full-scale commercial insulin production from *Spirulina*. This approach could pave the way for innovative, cost-effective solutions to meet the growing demand for insulin, especially in regions with high diabetes prevalence.

ACKNOWLEDGMENTS

The authors would like to thank the Department of Microbiology, School of Life Sciences, Vels University, Pallavaram, Chennai, Tamil Nadu, India, for providing necessary facilities.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS' CONTRIBUTION

KY conceptualized the study and performed literature review. AKK performed analysis, data interpretation and data validation. KY wrote the manuscript. AKK reviewed the manuscript. AKK and KY revised the manuscript. AKK approved the final manuscript for publication.

FUNDING

None.

DATA AVAILABILITY

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

ETHICS STATEMENT

Not applicable.

REFERENCES

1. Chan JCN, Lim LL, Wareham NJ, et al. The *Lancet* Commission on diabetes: using data to transform diabetes care and patient lives [published correction appears in *Lancet*. 2021;396(10267):2019-2082. doi: 10.1016/S0140-6736(20)32374-6

2. Sun H, Saeedi P, Karuranga S, et al. Erratum to "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045". *Diabetes Res Clin Pract.* 2023;204:110945. doi: 10.1016/j.diabres.2023.110945
3. Afroz A, Alramadan MJ, Hossain MN, et al. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review. *BMC Health Serv Res.* 2018;18(1):972. doi: 10.1186/s12913-018-3772-8
4. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 [published correction appears in *Lancet.* 2023;402(10408):1132. doi: 10.1016/S0140-6736(23)02044-5
5. Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *Lancet Diabetes Endocrinol.* 2023;11(7):474-489. doi: 10.1016/S2213-8587(23)00119-5
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2006;29(Suppl 1):S43-S48. doi: 10.2337/diacare.29.s1.06.s43
7. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: A Meta-analysis. *JAMA.* 2016;316(3):313-324. doi: 10.1001/jama.2016.9400
8. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. *Metabolism.* 2016;65(2):20-29. doi: 10.1016/j.metabol.2015.10.014
9. Banting FG, Best CH. Pancreatic extracts. *J. Lab. Clin. Med.* 1990;115:254-272. <https://pubmed.ncbi.nlm.nih.gov/2405086/>
10. Laing R, Waning B, Gray A, Ford N, 't Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. *Lancet.* 2003;361(9370):1723-1729. doi: 10.1016/S0140-6736(03)13375-2
11. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. *Lancet Diabetes Endocrinol.* 2016;4(3):275-285. doi: 10.1016/S2213-8587(15)00521-5
12. Sharma A, Bhandari PM, Neupane D, Kaplan WA, Mishra SR. Challenges constraining insulin access in Nepal-a country with no local insulin production. *Int Health.* 2018;10(3):182-190. doi: 10.1093/inthealth/ihy012
13. WHO Essential Medicines and health products information portal [Internet]. India: National list of essential medicines. 2015. <http://apps.who.int/medicinedocs/en/d/Js23088en/>. Accessed 16 June 2018.
14. La Forgia G, Nagpal S. Government-sponsored health insurance in India: are you covered? Washington, DC: World Bank Publications. 2012. doi: 10.1596/978-0-8213-9618-6
15. Ravi S, Ahluwalia R, Bergkvist S. Health and morbidity in India (2004-2014). Brookings India. Research Paper No. 092016. 2016.
16. Government of India, Department of Pharmaceuticals. Jan Aushadhi. Delhi: Bureau of Pharma PSUs of India. <http://janaushadhi.gov.in/>. Accessed April 19, 2017.
17. Singhal GL, Anita K, Nanda A. Jan Aushadhi store in India and quality of medicines therein. *Int J Pharm Pharm Sci.* 2011;3(1):204-207.
18. Hozayen WG, Mahmoud AM, Soliman HA, Mostafa SR. *Spirulina versicolor* improves insulin sensitivity and attenuates hyperglycemia-mediated oxidative stress in fructose-fed rats. *J Intercult Ethnopharmacol.* 2016;5(1):57-64. doi: 10.5455/jice.20151230055930
19. Yuvarani K, Kathireshan AK. Genomic exploration of insulin-like proteins in *Arthrospira platensis* SPKY1. *Curr Res Cmpl Alt Med.* 2024;8:231. doi: 10.29011/2577-2201.100231
20. Zarrouk C. Contribution to the study of a cyanobacterium: influence of various physical and chemical factors on the growth and photosynthesis of *Spirulina maxima* (Setchell and Gardner) Geitler. [PhD thesis]. University of Paris; France: 1966.
21. Donmez GC, Aksu Z, Ozturk A, Kutsal T. A comparative study on heavy metal biosorption characteristics of some algae. *Process Biochem.* 1999;34(9):885-892. doi: 10.1016/S0032-9592(99)00005-9
22. National Center for Biotechnology Information. PubChem Patent Summary for US-3945988-A, Process for isolation of insulin from plant source. <https://pubchem.ncbi.nlm.nih.gov/patent/US-3945988-A>. Accessed Jan. 31, 2025.
23. Ozcan M, Canpolat S, Bulmus O, et al. Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in mice. *Fundam Clin Pharmacol.* 2019;33(2):170-180. doi: 10.1111/fcp.12413
24. Sharma A, Kaplan WA. Challenges constraining access to insulin in the private-sector market of Delhi, India. *BMJ Glob Health.* 2016;1(3):e000112. doi: 10.1136/bmjgh-2016-000112
25. Walsh G. Therapeutic insulins and their large-scale manufacture. *Appl Microbiol Biotechnol.* 2005;67(2):151-159. doi: 10.1007/s00253-004-1809-x
26. Nilsson J, Jonasson P, Samuelsson E, Sthl S, Uhlen M. Integrated production of human insulin and its C-peptide. *J Biotechnol.* 1996;48(3):241-250. doi: 10.1016/0168-1656(96)01514-3
27. Ferrer-Miralles N, Villaverde A. Bacterial cell factories for recombinant protein production; expanding the catalogue. *Microb Cell Fact.* 2013;12:113. doi: 10.1186/1475-2859-12-113
28. AlFadhly NKZ, Alhelfi N, Altemimi AB, Verma DK, Cacciola F, Narayanankutty A. Trends and Technological Advancements in the Possible Food Applications of *Spirulina* and Their Health Benefits: A Review. *Molecules.* 2022;27(17):5584. doi: 10.3390/molecules27175584
29. Soni AR, Sudhakar K, Rana RSA. *Spirulina* - From growth to nutritional product: A review. *Trends Food Sci Technol.* 2017;69(Part A):157-171. doi: 10.1016/j.tifs.2017.09.010

30. Layam A, Reddy CLK. Antidiabetic property of *Spirulina*. *Diabetol Croat.* 2007;35(2):29-33.
31. Guldás M, Ziyānok S, Sahan Y, Yıldız E, Gurbuz O. Antioxidant and anti-diabetic properties of *Spirulina platensis* produced in Turkey. *Food Sci Technol.* 2021;41(3):615-625. doi: 10.1590/fst.23920
32. Simon JP, Baskaran UL, Shallaudin KB, Ramalingam G, Evan Prince S. Evidence of antidiabetic activity of *Spirulina fusiformis* against streptozotocin-induced diabetic Wistar albino rats. *3 Biotech.* 2018;8(2):129. doi: 10.1007/s13205-018-1156-8
33. Anwer R, Alam M, Khursheed S, Shaikh MK, Kabir H, Fatma T. *Spirulina*: Possible pharmacological evaluation for insulin-like protein. *J Appl Phycol.* 2012;25(3). doi: 10.1007/s10811-012-9924-z
34. Hozayen WG, Mahmoud AM, Soliman HA, Mostafa SR. *Spirulina versicolor* improves insulin sensitivity and attenuates hyperglycemia-mediated oxidative stress in fructose-fed rats. *J Intercult Ethnopharmacol.* 2016;5(1):57-64. doi: 10.5455/jice.20151230055930
35. Pandey JP, Tiwari A, Mishra G, Mishra R. Role of *Spirulina maxima* in the control of blood glucose levels and body weight in streptozotocin-induced diabetic male Wistar rats. *J Algal Biomass Util.* 2011;2(4):35-37.
36. Silva LB, Santos SSS, Azevedo CR, et al. The leaves of green plants as well as a cyanobacterium, a red alga, and fungi contain insulin-like antigens. *Braz J Med Biol Res.* 2002;35(3):297-303. doi: 10.1590/S0100-879X2002000300004
37. Anwer R, Khursheed S, Fatma T. Detection of immunoactive insulin in *Spirulina*. *J Appl Phycol.* 2011;24(3). doi: 10.1007/s10811-011-9757-1
38. Kaushik BD, Sharma RK. Influence of salinity on selected enzymes in cyanobacteria. *Indian J Microbiol.* 1997;37:99-100.
39. El-Monem A, Gharieb M, Hussian AE, Doman K. Effect of pH on phytochemical and antibacterial activities of *Spirulina platensis*. *Int J Appl Environ Sci.* 2018;13(4):339-351.
40. Abd El-Baky H, El-Baz FK, El-Baroty GS. *Spirulina* species as a source of carotenoids and a-tocopherol and its anticarcinoma factors. *Biotechnol.* 2003;2(3):222-240. doi: 10.3923/biotech.2003.222.240
41. Rafiqul IM, Jalal KCA, Alam MZ. Environmental factors for optimisation of *Spirulina* biomass in laboratory culture. *Biotechnol.* 2005;4(1):19-22. doi: 10.3923/biotech.2005.19.22
42. Thirumala M. Optimization of growth of *Spirulina platensis* for production of carotenoids. *Int J Life Sci Biotechnol Pharm Res.* 2012;1(2):152-157.
43. Hsieh-Lo M, Castillo G, Ochoa-Becerra MA, Mojica L. Phycocyanin and phycoerythrin: Strategies to improve production yield and chemical stability. *Algal Res.* 2019;42:101600. doi: 10.1016/j.algal.2019.101600
44. Masojidek J, Torzillo G, Koblizek M. Photosynthesis in microalgae. *Handbook of Microalgal Culture: Biotechnology and Applied Phycology.* 2013:20-39. doi: 10.1002/9781118567166.ch2
45. de Mooij T, Janssen M, Cerezo O, et al. Antenna size reduction as a strategy to increase biomass productivity: A great potential not yet realized. *J Appl Phycol.* 2015;27(3):1063-1077. doi: 10.1007/s10811-014-0427-y
46. Liu Q, Huang Y, Zhang R, Cai T, Cai Y. Medical Application of *Spirulina platensis* Derived C-Phycocyanin. *Evid Based Complement Alternat Med.* 2016;2016(1):7803846. doi: 10.1155/2016/7803846
47. Goksan T, Zekeriyaoglu A, Ilknur Ak . The growth of *Spirulina platensis* in different culture systems under greenhouse condition. *Turk J Biol.* 2007;31:47-52.
48. Andrade MR, Costa JA. Outdoor and indoor cultivation of *Spirulina platensis* in the extreme south of Brazil. *Z Naturforsch C J Biosci.* 2008;63(1-2):85-90. doi: 10.1515/znc-2008-1-216
49. Wu B, Tseng CK, Xiang W. Large-scale cultivation of *Spirulina* in seawater-based culture medium. *Botanica Marina.* 1993;36(2):99-102. doi: 10.1515/botm.1993.36.2.99
50. Dineshkumar R, Sampathkumar P, Rajendran N. Cultivation of *Spirulina platensis* in different selective media. *Indian J Mar Sci.* 2016;45(12).
51. Harutyunyan A, Gabrielyan L, Aghajanyan A, et al. Comparative Study of Physicochemical Properties and Antibacterial Potential of Cyanobacteria *Spirulina platensis*-Derived and Chemically Synthesized Silver Nanoparticles. *ACS Omega.* 2024;9(27):29410-29421. doi: 10.1021/acsomega.4c01604
52. Shi X, Zhang X, Chen F. Heterotrophic production of biomass and lutein by *Chlorella protothecoides* on various nitrogen sources. *Enzyme Microb Technol.* 2000;27(3-5):312-318. doi: 10.1016/S0141-0229(00)00208-8
53. Isleten-Hosoglu M, Gultepe I, Elibol M. Optimization of carbon and nitrogen sources for biomass and lipid production by *Chlorella saccharophila* under heterotrophic conditions and development of Nile red fluorescence-based method for quantification of its neutral lipid content. *Biochem Eng J.* 2012;61:11-19. doi: 10.1016/j.bej.2011.12.001
54. Tan CK, Johns MR. Fatty acid production by heterotrophic *Chlorella saccharophila*. *Hydrobiologia.* 1991;215:13-19. doi: 10.1007/BF00005896
55. Qiao H, Wang G. Effect of carbon source on growth and lipid accumulation in *Chlorella sorokiniana* GXNN01. *Chinese J Oceanol Limnol.* 2009;27(4):762-768. doi: 10.1007/s00343-009-9216-x